Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161831 · ClinicalTrials.gov registry record · NA
HPV Vaccine Reminders - SEARCH II Study
A NA study of Human Papillomavirus Vaccination, sponsored by Columbia University.
- Active
- Registry status
- NA
- Development phase
- 396
- Enrollment target
- 2
- Study locations
NCT06161831: Active NA study of Human Papillomavirus Vaccination, sponsored by Columbia University.
NCT06161831 is a NA study of Human Papillomavirus Vaccination that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 396 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06161831, a NA study of Human Papillomavirus Vaccination, is active but no longer recruiting, sponsored by Columbia University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 396 participants
- Enrollment target
- 2
- Study locations
Study Summary
This RCT will take place at health centres and their affiliated schools and community immunization centers overseen by the Kampala Capital City Authority (KCCA) as well as at the Makerere/Mulago/Columbia Adolescent Health Clinic in Kampala. The investigators will assess the impact of vaccine text message and automated phone reminders on human papillomavirus (HPV) vaccination initiation and completion.
Primary Outcome
Timeliness of vaccination (time to event) will be measured
Conditions Studied
Interventions
- BEHAVIORAL Text Message/automated phone reminder
Study Locations (2)
New York
- Columbia University Irving Medical Center - New York
Other
- Makerere University/Mulago Hospital - Kampala
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2024-04-22 |
| Est. Completion | 2026-07-31 |
| Phase | NA |
What the registry record for NCT06161831 still lists
NCT06161831 is an interventional study that assigns participants to a tested intervention. The registered 396 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Human Papillomavirus Vaccination appearing as the primary indexed condition, and to 1 intervention - of which Text Message/automated phone reminder is the first listed.
NCT06161831 reports a single indexed study location in New York, Other.
Frequently Asked Questions
What is clinical trial NCT06161831 about?
NCT06161831 is a clinical study titled "HPV Vaccine Reminders - SEARCH II Study". This RCT will take place at health centres and their affiliated schools and community immunization centers overseen by the Kampala Capital City Authority (KCCA) as well as at the Makerere/Mulago/Columbia Adolescent Health Clinic in Kampala. The investigators will assess the impact of vaccine text me...
What is the current status of trial NCT06161831?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 396 participants. The study started on 2024-04-22. Estimated completion is 2026-07-31.
What conditions does trial NCT06161831 study?
This clinical trial studies the following conditions: Human Papillomavirus Vaccination.
What interventions are being tested in trial NCT06161831?
The interventions under investigation include: Text Message/automated phone reminder (BEHAVIORAL).
Who is sponsoring clinical trial NCT06161831?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06161831 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papillomavirus Vaccination
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06161831's enrollment target sits among peer trials
396 268th of 2000 higher than 1,733 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
- NCT06666790 · 396 participants · NA
DermaSensor Postmarket Surveillance Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI